Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
Between 74-89 % of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
Between 74-89 % of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
English (International)
Bio-Techne Corp
Open
SectorHealthcare
48.72 1.08
Overview
Share price change
24h
Min
48.23
Max
49.48
Income | -12M 23M |
|---|---|
Sales | 19M 316M |
P/E Sector Avg | 58.566 51.198 |
EPS | 0.56 |
Dividend yield | 0.66 |
Profit margin | 7.144 |
Employees | 3,100 |
EBITDA | -36M 39M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +42.41% upside |
Dividend yield Sector Avg | 0.66% 2.40% |
|---|---|
Next Earnings | 6 Aug 2025 |
Next Dividend date | 29 Aug 2025 |
Next Ex Dividend date | 18 Aug 2025 |
Market Cap | -2.9B 7.6B |
|---|---|
Previous open | 47.64 |
Previous close | 48.72 |
News Sentiment
By Acuity
50%
50%
167 / 380 Healthcare
Technical Score
By Trading Central
Confidence
Weak Bullish Evidence
Bio-Techne Corp Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Bio-Techne Corp Forecast
Price Target
By TipRanks
42.41% upside
12 Months Forecast
Average 68.8 USD 42.41%
High 90 USD
Low 51 USD
Based on 11 Wall Street analysts offering 12 month price targets forBio-Techne Corp - Dist in the last 3 months.
Sentiment
By Acuity
167 / 380 Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Bio-Techne Corp
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
